Abstract P3-13-09: Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

CONCLUSIONS: The combination of oral continuous dosing of V (200 mg PO BID) with metronomic C (50, 75, 100 and 125 mg daily) is well tolerated and shows antitumor activity in patients with BRCA mutation associated MBC. The RPTD is C 125 mg daily plus V 200 mg BID, although further escalation of the C dose may be feasible since DLT was not seen at this dose level.canres;77/4_Supplement/P3-13-09/table1T1Dose LevelsDose Level# Patients/Evaluable# DLTType of DLTDL 1 :V 50mg , C 50mg3/30DL 2 :V 100 mg, C 50mg4/30DL 3 :V 200 mg, C 50mg6/61HeadacheDL 4 :V 300 mg, C 50mg6/52Nausea (N=2)DL 3A :V 200 mg; C 75mg3/30DL 3B :V 200 mg, C 100mg6/30DL 3C :V 200 mg, C 125mg3/30Citation Format: Calvo MF, Allemand C, Valerio AC, Hernandez MN, Corrao FH, Castro Barba M, Wernicke A, Orti R, Ilzarbe F, Gogorza SJ, Albrecht A, Izbizky GH, Lorusso C. Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-09.

Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: MF Calvo, C Allemand, AC Valerio, MN Hernandez, FH Corrao, M Castro Barba, A Wernicke, R Orti, F Ilzarbe, SJ Gogorza, A Albrecht, GH Izbizky, C Lorusso Tags: Poster Session Abstracts Source Type: research